These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26921096)

  • 21. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PIK3CA mutation is an independent indicator of malignant phenotype and prognosis in breast cancer].
    Li SY; Wang W; Li JM; Wang Z; Wen RY; Chen J; Miao XT
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):605-8. PubMed ID: 22325221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition.
    Spangle JM; Von T; Pavlick DC; Khotimsky A; Zhao JJ; Roberts TM
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24427-24433. PubMed ID: 32929011
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
    Board RE; Wardley AM; Dixon JM; Armstrong AC; Howell S; Renshaw L; Donald E; Greystoke A; Ranson M; Hughes A; Dive C
    Breast Cancer Res Treat; 2010 Apr; 120(2):461-7. PubMed ID: 20107891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway.
    Cizkova M; Cizeron-Clairac G; Vacher S; Susini A; Andrieu C; Lidereau R; Bièche I
    PLoS One; 2010 Dec; 5(12):e15647. PubMed ID: 21209903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
    Dogruluk T; Tsang YH; Espitia M; Chen F; Chen T; Chong Z; Appadurai V; Dogruluk A; Eterovic AK; Bonnen PE; Creighton CJ; Chen K; Mills GB; Scott KL
    Cancer Res; 2015 Dec; 75(24):5341-54. PubMed ID: 26627007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
    Levine DA; Bogomolniy F; Yee CJ; Lash A; Barakat RR; Borgen PI; Boyd J
    Clin Cancer Res; 2005 Apr; 11(8):2875-8. PubMed ID: 15837735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA Mutations in Resected Small Cell Lung Cancer.
    Han N; Cheng QY; Chen B; Cai JF; Wang XJ; Lou CJ; Qin J; Ye WW; Lei L; Lu HY
    Adv Clin Exp Med; 2016; 25(3):397-402. PubMed ID: 27629725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The PIK3CA gene is mutated with high frequency in human breast cancers.
    Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
    Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic deregulation of the PIK3CA oncogene in oral cancer.
    Murugan AK; Munirajan AK; Tsuchida N
    Cancer Lett; 2013 Sep; 338(2):193-203. PubMed ID: 23597702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
    Gasser JA; Inuzuka H; Lau AW; Wei W; Beroukhim R; Toker A
    Mol Cell; 2014 Nov; 56(4):595-607. PubMed ID: 25458846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
    Koren S; Bentires-Alj M
    FEBS J; 2013 Jun; 280(12):2758-65. PubMed ID: 23384338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.